Plasma high mobility group box 1 protein reflects fibrosis in pediatric nonalcoholic fatty liver disease

Expert Review of Molecular Diagnostics

Volumn 14, Issue 6, 2014, Pages 763-771

  Alisi, Anna ^a   Nobili, Valerio ^a   Ceccarelli, Sara ^a   Panera, Nadia ^a   De Stefanis, Cristiano ^a   De Vito, Rita ^a   Vitali, Roberta ^b   Bedogni, Giorgio ^c   Balsano, Clara ^d   Cucchiara, Salvatore ^e   Stronati, Laura ^b  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b ENEA   (Italy)

^c Liver Research Center   (Italy)

^d CNR   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

High mobility group box 1; Liver fibrosis; Monocyte chemoattractant protein 1; Non alcoholic fatty liver disease; TGF

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; HIGH MOBILITY GROUP B1 PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; TRANSFORMING GROWTH FACTOR BETA;

ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHILD; CHILDHOOD DISEASE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; INFLAMMATION; LIVER BIOPSY; LIVER FIBROSIS; LIVER HISTOLOGY; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PROTEIN BLOOD LEVEL; REVIEW; BIOPSY; BLOOD; CASE CONTROL STUDY; COMPLICATION; CROSS-SECTIONAL STUDY; LIVER CIRRHOSIS; PATHOLOGY; PRESCHOOL CHILD;

BIOPSY; CASE-CONTROL STUDIES; CHEMOKINE CCL2; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; FEMALE; HMGB1 PROTEIN; HUMANS; LIVER CIRRHOSIS; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE; TRANSFORMING GROWTH FACTOR BETA;

EID: 84903216539     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.2014.928205     Document Type: Review

References (61)

1. Bellentani S, Scaglioni F, Marino M, et al. Epidemiology of non-Alcoholic fatty liver disease. Dig Dis 2010;28:155-61
2. Nobili V, Svegliati-Baroni G, Alisi A, et al. A 360-degree overview of paediatric NAFLD: Recent insights. J Hepatol 2013;58:1218-29
3. Alisi A, Feldstein AE, Villani A, et al. Pediatric nonalcoholic fatty liver disease: A multidisciplinary approach. Nat Rev Gastroenterol Hepatol 2012;9:152-61
4. Hsu E, Murray K. Is nonalcoholic fatty liver disease in children the same disease as in adults? Clin Liver Dis 2012;16: 587-98
5. Carter-Kent C, Brunt EM, Yerian LM, et al. Relations of steatosis type, grade, and zonality to histological features in pediatric nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 2011;52:190-7
6. Ibrahim SH, Kohli R, Gores GJ. Mechanisms of lipotoxicity in NAFLD and clinical implications. J Pediatr Gastroenterol Nutr 2011;53:131-40
7. Rolo AP, Teodoro JS, Palmeira CM. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic Biol Med 2012;52:59-69
8. Fujii H, Kawada N. Inflammation and fibrogenesis in steatohepatitis. J Gastroenterol 2012;47:215-25
9. Frasinariu OE, Ceccarelli S, Alisi A, et al. Gut-liver axis and fibrosis in nonalcoholic fatty liver disease: An input for novel therapies. Dig Liver Dis 2013;45: 543-51
10. Tang D, Kang R, Coyne CB, et al. PAMPs and DAMPs: Signal 0s that spur autophagy and immunity. Immunol Rev 2012;249: 158-75
11. Alisi A, Carsetti R, Nobili V. Pathogen-or damage-Associated molecular patterns during nonalcoholic fatty liver disease development. Hepatology 2011;54:1500-2
12. Chen GY, Nunez G. Sterile inflammation: Sensing and recting to damage. Nat Rev Immunol 2010;10:826-37
13. Gao B, Seki E, Brenner DA, et al. Innate immunity in alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol 2011;300: G516-25
14. Brenner DA, Seki E, Taura K, et al. Non-Alcoholic steatohepatitis-induced fibrosis: Toll-like receptors, reactive oxygen species and Jun N-Terminal kinase. Hepatol Res 2010;41:683-6
15. Maher JJ. DAMPs ramp up drug toxicity. J Clin Invest 2009;119:246-9
16. Kubes P, Mehal WZ. Sterile inflammation in the liver. Gastroenterology 2012;143: 1158-72
17. Zhang CC, Krieg S, Shapiro DJ. HMG-1 stimulates estrogen response element binding by estrogen receptor from stably transfected HeLa cells. Mol Endocrinol 1999;13:632-43 (Pubitemid 30636429)
18. Bustin M. Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins. Mol Cell Biol 1999;19:5237-46 (Pubitemid 29339883)
19. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): Nuclear weapon in the immune arsenal. Nat Rev Immunol 2005;5:331-42 (Pubitemid 40516158)
20. Harris HE, Andersson U, Pisetsky DS. HMGB1: A multifunctional alarmin driving autoimmune and inflammatory disease. Nat Rev Rheumatol 2012;8:195-202
21. Gauley J, Pisetsky DS. The translocation of HMGB1 during cell activation and cell death. Autoimmunity 2009;42:299-301
22. Bianchi ME. HMGB1 loves company. J Leukoc Biol 2009;86:573-6
23. Venereau E, Casalgrandi M, Schiraldi M, et al. Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J Exp Med 2012;209:1519-28
24. Schiraldi M, Raucci A, Muñoz LM, et al. HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4. J Exp Med 2012;209: 551-63
25. Berthelot F, Fattoum L, Casulli S, et al. The effect of HMGB1, a damage-Associated molecular pattern molecule, on polymorphonuclear neutrophil migration depends on its concentration. J Innate Immun 2012;4:41-58
26. Blanco P, Palucka AK, Pascual V, et al. Dendritic cells and cytokinesin human inflammatory diseases. Cytokine Growth Factor Rev 2008;19:41-52
27. Zhu XM, Yao FH, Yao YM, et al. Endoplasmic reticulum stress and its regulator XBP-1 contributes to dendritic cell maturation and activation induced by high mobility group box-1 protein. Int J Biochem Cell Biol 2012;44:1097-105
28. Sundberg E, Fasth AE, Palmblad K, et al. High mobility group box chromosomal protein 1 act as a proliferator signal for activated T lymphocytes. Immunobiology 2009;214:303-9
29. Ramasamy R, Yan SF, Schmidt AM. Receptor for AGE (RAGE): Signaling mechanisms in the pathogenesis of diabetes and its complications. Ann N Y Acad Sci 2011;1243:88-102
30. Huang W, Tang Y, Li L. HMGB1, a potent proinflammatory cytokine in sepsis. Cytokine 2010;51:119-26
31. Sims GP, Rowe DC, Rietdijk ST, et al. HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol 2010;28:367-88
32. Klune JR, Dhupar R, Cardinal J, et al. HMGB1: Endogenous danger signaling. Mol Med 2008;14:476-84
33. Vitali R, Stronati L, Negroni A, et al. Fecal HMGB1 is a novel marker of intestinal mucosal inflammation in pediatric inflammatory bowel disease. Am J Gastroenterol 2011;106:2029-40
34. Nin JW, Ferreira I, Schalkwijk CG, et al. Higher plasma high-mobility group box 1 levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: A 12 year follow-up study. Diabetologia 2012;55:2489-93
35. Huang JM, Hu J, Chen N, et al. Relationship between plasma high-mobility group box-1 levels and clinical outcomes of ischemic stroke. J Crit Care 2013;28:792-7
36. Oshima G, Shinoda M, Tanabe M, et al. Increased plasma levels of high mobility group box 1 in patients with acute liver failure. Eur Surg Res 2012;48:154-62
37. Antoine DJ, Dear JW, Lewis PS, et al. Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital. Hepatology 2013;58:777-87
38. Lohman TG, Roche AF, Martorell R. Anthropometric standardization reference manual. Human Kinetics Books; Champaign, IL, USA: 1988
39. Cacciari E, Milani S, Balsamo A, et al. Italian cross-sectional growth charts for height, weight and BMI (2 to 20 yr). J Endocrinol Invest 2006;29:581-93 (Pubitemid 44446267)
40. Matthews DR, Hosker JP, Rudenski AS. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-19 (Pubitemid 15018832)
41. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-21 (Pubitemid 40770284)
42. Koenker R. Quantile regression. Cambridge Books, Cambridge University Press, 2005; number 9780521608275
43. Royston P, Sauerbrei W. Multivariable model-building: A pragmatic approach to regression analysis based on fractional polynomials for modelling continuous variables. Wiley; Chichester, UK: 2008
44. Zhang Z, Lin C, Peng L, et al. High mobility group box 1 activates Toll like receptor 4 signaling in hepatic stellate cells. Life Sci 2012;91:207-12
45. Nobili V, Alisi A, Torre G, et al. Hyaluronic acid predicts hepatic fibrosis in children with nonalcoholic fatty liver disease. Transl Res 2010;156:229-34
46. Feldstein AE, Alkhouri N, De Vito R, et al. Serum cytokeratin-18 fragment levels are useful biomarkers for nonalcoholic steatohepatitis in children. Am J Gastroenterol 2013;108:1526-31
47. Alisi A, Locatelli M, Nobili V. Nonalcoholic fatty liver disease in children. Curr Opin Clin Nutr Metab Care 2010;13: 397-402
48. Musso G, Gambino R, Cassader M. Gut microbiota as a regulator of energy homeostasis and ectopic fat deposition: Mechanisms and implications for metabolic disorders. Curr Opin Lipidol 2010;21:76-83
49. Sakaguchi S, Takahashi S, Sasaki T, et al. Progression of alcoholic and non-Alcoholic steatohepatitis: Common metabolic aspects of innate immune system and oxidative stress. Drug Metab Pharmacokinet 2011;26: 30-46
50. Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: Biochemical, metabolic, and clinical implications. Hepatology 2010;51:679-89
51. Larter CZ, Chitturi S, Heydet D, et al. A fresh look at NASH pathogenesis. Part 1: The metabolic movers. J Gastroenterol Hepatol 2010;25:672-90
52. Li L, Chen L, Hu L, et al. Nuclear factor high-mobility group box1 mediating the activation of Toll-like receptor 4 signaling in hepatocytes in the early stage of nonalcoholic fatty liver disease in mice. Hepatology 2011;54:1620-30
53. Alisi A, Manco M, Devito R, et al. Endotoxin and plasminogen activator inhibitor-1 serum levels associated with nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr 2010;50:645-9
54. Arshad MI, Piquet-Pellorce C, Samson M. IL-33 and HMGB1 alarmins: Sensors of cellular death and their involvement in liver pathology. Liver Int 2012;32:1200-10
55. Craig DG, Lee P, Pryde EA, et al. Circulating apoptotic and necrotic cell death markers in patients with acute liver injury. Liver Int 2011;31:1127-36
56. Brenner C, Galluzzi L, Kepp O, et al. Decoding cell death signals in liver inflammation. J Hepatol 2013;59:583-94
57. Ge WS, Wu JX, Fan JG, et al. Inhibition of high-mobility group box 1 expression by siRNA in rat hepatic stellate cells. World J Gastroenterol 2011;17:4090-8
58. Wang FP, Li L, Li J, et al. High mobility group box-1 promotes the proliferation and migration of hepatic stellate cells via TLR4-dependent signal pathways of PI3K/Akt and JNK. PLoS ONE 2013;8: E64373
59. Yang H, Ochani M, Li J, et al. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci USA 2004;101:296-301 (Pubitemid 38084244)
60. Kao KK, Fink MP. The biochemical basis for the anti-inflammatory and cytoprotective actions of ethyl pyruvate and related compounds. Biochem Pharmacol 2010;80: 151-9
61. Albayrak A, Uyanik MH, Cerrah S, et al. Is HMGB1 a new indirect marker for revealing fibrosis in chronic hepatitis and a new therapeutic target in treatment? Viral Immunol 2010;23:633-8.